Shanghai-based asset manager focused on active equity and fixed-income strategies for institutional and high-net-worth clients across China and Greater China markets. GF Fund Management Co. Ltd. is known for proprietary research-driven portfolio construction, multi-asset fund offerings and segregated mandate capabilities, with emphasis on domestic A-shares, bonds and fund-of-funds solutions. Positioned as a domestic full-service manager, it competes on distribution, product innovation and onshore regulatory compliance.
Shanghai-based asset manager focused on active equity and fixed-income strategies for institutional and high-net-worth clients across China and Greater China markets. GF Fund Management Co. Ltd. is known for proprietary research-driven portfolio construction, multi-asset fund offerings and segregated mandate capabilities, with emphasis on domestic A-shares, bonds and fund-of-funds solutions. Positioned as a domestic full-service manager, it competes on distribution, product innovation and onshore regulatory compliance.
Research-led, onshore multi-asset manager prioritizing active equity and fixed-income allocations across China and Greater China markets. Portfolios are constructed from bottom-up proprietary research integrated with macro and policy analysis, favoring high-conviction A-share positions, credit selection in domestic bond markets, and fund-of-funds sleeves for diversification. Capital is deployed through segregated mandates and retail products with a bias toward medium-to-long horizons, disciplined risk controls, scenario stress testing, and distribution-led product innovation to align solutions with institutional and high-net-worth client objectives.
Research-led, onshore multi-asset manager prioritizing active equity and fixed-income allocations across China and Greater China markets. Portfolios are constructed from bottom-up proprietary research integrated with macro and policy analysis, favoring high-conviction A-share positions, credit selection in domestic bond markets, and fund-of-funds sleeves for diversification. Capital is deployed through segregated mandates and retail products with a bias toward medium-to-long horizons, disciplined risk controls, scenario stress testing, and distribution-led product innovation to align solutions with institutional and high-net-worth client objectives.
| Trades 4006 | Longs Won 2356/4006 58% | Profit Factor 4.66 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $9.36M |
| Average Win $1.38M | Best Trade (Aug 17) $390.84M | Sharpe Ratio -141.38 |
| Average Loss -$423,167.95 | Worst Trade (Sep 01) -$96.17M | Z-Score 11.67 (100%) |
| Commissions $0 | Avg. Trade Length 11m 2w | Expectancy $649,676.46 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 17,857 | 16,071 | 14,286 | 12,500 | 10,714 | 8,929 | 7,143 | 5,357 | 3,571 | 1,786 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 8176 81761L201 | 8,031 | $13,572 | $13,572 | - | - | - | 0.0 |
A Agilent Technologies Inc. | 7,785 | $1.04M | $1.14M | - | $96,293.75 | 9.26% | +3.276% |
AAPL Apple Inc. | 1.42M | $356.43M | $446.16M | - | $89.73M | 25.18% | +0.294% |
AARD Aardvark Therapeutics, Inc. | 452 | $5,408.28 | $3,570.8 | - | -$1,837.48 | -33.98% | +8.219% |
AAT American Assets Trust, Inc. | 665 | $17,242.91 | $15,188.6 | - | -$2,054.31 | -11.91% | +1.421% |
ABBV AbbVie Inc. | 48,257 | $8.92M | $11.87M | - | $2.95M | 33.02% | +0.828% |
ABCL AbCellera Biologics Inc. | 6,414 | $18,296.16 | $44,513.16 | - | $26,217 | 143.29% | +6.279% |
ABNB Airbnb, Inc. | 84,401 | $10.67M | $15.03M | - | $4.36M | 40.91% | +17.443% |
ABSI Absci Corporation | 3,184 | $8,554.15 | $28,464.96 | - | $19,910.81 | 232.76% | +7.711% |
ABT Abbott Laboratories | 47,558 | $5.6M | $5.13M | - | -$474,954.87 | -8.48% | -0.139% |
ABUS Arbutus Biopharma Corporation | 4,071 | $14,145.98 | $18,828.37 | - | $4,682.39 | 33.1% | +1.872% |
ABVX Abivax SA ADR | 1,302 | $171,655.92 | $170,470.85 | - | -$1,185.07 | -0.69% | +0.715% |
ACAD Acadia Pharmaceuticals Inc. | 3,609 | $66,749.73 | $105,454.98 | - | $38,705.25 | 57.99% | +2.707% |
ACIU Acimmune SA | 2,084 | $5,327.52 | $4,918.24 | - | -$409.28 | -7.68% | +1.724% |
ACN Accenture plc Class A | 947 | $234,258.16 | $166,368.95 | - | -$67,889.21 | -28.98% | +2.671% |
ACRS Aclaris Therapeutics, Inc. | 2,553 | $8,168.9 | $15,075.46 | - | $6,906.56 | 84.55% | -3.038% |
ADBE Adobe Inc. | 81,831 | $34.27M | $21.7M | - | -$12.57M | -36.68% | +1.887% |
ADC Agree Realty Corporation | 1,617 | $114,817.93 | $122,261.37 | - | $7,443.44 | 6.48% | -0.969% |
ADEA Adeia Inc. | 15,460 | $509,098 | $436,126.6 | - | -$72,971.4 | -14.33% | -0.248% |
ADI Analog Devices, Inc. | 98,367 | $21.22M | $38.34M | - | $17.13M | 80.73% | +3.313% |